Romiplostim

CHEMBL1201832 Phase 4 Approved Protein
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A thrombopoietin receptor agonist given as a weekly injection to stimulate platelet production in adults with chronic immune thrombocytopenia who have not responded to other treatments. It mimics the natural hormone thrombopoietin to signal the bone marrow to produce more platelets.

Therapeutic Areas

Mechanism of Action

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A thrombopoietin receptor agonist given as a weekly injection to stimulate platelet production in adults with chronic immune thrombocytopenia who have not responded to other treatments. It mimics the natural hormone thrombopoietin to signal the bone marrow to produce more platelets.

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Yes, Romiplostim is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201832. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.